SAN DIEGO, Feb. 18 2022 (GLOBE NEWSWIRE) — Organovo Holdings, Inc. (NASDAQ: ONVO), a three-dimensional biology company focused on achieving scientific and medical breakthroughs using 3D bioprinting technology, today announced the hiring Curtis Tyree, PhD, as Sr. Vice President of Strategy and Business Development. Dr. Tyree has over 20 years of management and R&D experience in the drug discovery industry in various therapeutic areas at Ligand Pharmaceuticals, TorreyPines Therapeutics (formerly Neurogenetics) and most recently served as SVP, Strategic Planning at HUYABIO International.
“Curtis will bring significant strategic and business value to Organovo,” said Keith Murphy, Executive Chairman of Organovo. “His experience in advancing drug development programs, including in-licensing and in-licensing and working with pharmaceutical companies, will be extremely valuable to us as we move forward with our plan to leverage 3D intestinal tissue for the treatment of ulcerative colitis and Crohn’s disease.” Organovo expects to have pipeline opportunities for out-licensing and out-licensing, particularly in its first therapeutic area of inflammatory bowel disease (IBD).
“Organovo has the technological expertise, scientific insight and talent base to advance both new targets and therapies in important disease areas,” said Dr. Tyree. “I look forward to developing both internal and external partnerships to accelerate the development of new therapies. I also welcome the opportunity to help the management team develop and realize the company’s vision.”
Organovo is an early-stage biotechnology company that develops and uses highly customized 3D human tissues as dynamic models of healthy and diseased human biology for drug development. The company’s proprietary technology is used to create functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Organovo’s advances include cell type-specific compartments, predominant intercellular tight junctions, and the formation of microvascular structures. Management believes that these attributes can enable critical models of complex multicellular diseases that can be used to develop clinically effective drugs for selected therapeutic areas.
All statements in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements in this release are based on expectations current, but are subject to a number of risks and uncertainties. These risks and uncertainties and other factors are identified and described in greater detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 15, 2021, as these factors risk are updated in their most recently filed Quarterly Report on Form 10-Q filed with the SEC on February 14, 2022. You should not place undue reliance on these forward-looking statements, which speak only as of the date they were made. These cautionary statements should be considered together with any written or oral forward-looking statements the Company may make in the future. Except as required by applicable law, including United States securities laws, the Company does not intend to update any of the forward-looking statements to conform to such statements in order to reflect actual results, subsequent events or circumstances or to reflect the occurrence of unforeseen events. events.
Amato and Partners, LLC
Investor Relations Advisor